M.D. Anderson Holds First Cancer Meeting in Spanish

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 4 No 7
Volume 4
Issue 7

HOUSTON--Spanish-speaking oncologists from around the world stopped off in Houston on their way home from the ASCO meeting to learn more about state-of-the-art cancer care--in their own language.

HOUSTON--Spanish-speaking oncologists from around the world stoppedoff in Houston on their way home from the ASCO meeting to learnmore about state-of-the-art cancer care--in their own language.

The University of Texas M.D. Anderson Cancer Center sponsoredthe 2-day Conferencia Internacional de Oncologist Medica, thefirst ever to be presented exclusively in Spanish at the cancercenter.

"M.D. Anderson is probably the only center in the countrythat could put together such a program in Spanish. At least onephysician or researcher in each of our major services speaks fluentSpanish, and these faculty are on the conference program,"said Dr. Richard Pazdur, assistant vice president of academicaffairs and a conference organizer.

About 5% of M.D. Anderson's patients come from other countriesand most of them speak Spanish. To assist these patients, theCenter has established the International Patient Center, a patientfamily hotel where multilingual staff serve as advocates for patientsfar from home.

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Recent Videos
Specialties including neurosurgery, radiation oncology, and neuro-rehabilitation all play a notable role in the care of patients with brain tumors.
Treatment-related toxicities during neuro-oncology therapy appear well managed with dose modifications and treatment cycle holds.
The phase 3 NIVOSTOP trial evaluated an anti–PD-1 immunotherapy, nivolumab, in a patient population similar in the KEYNOTE-689 trial.
CAR T-cell therapies appear to be an evolving modality in the treatment of those with intracranial tumors, said Sylvia Kurz, MD, PhD.
Opportunities to further reduce relapses include pembrolizumab-based combination therapy and evaluating the agent’s contribution before and after surgery.
For patients with locally advanced head and neck cancers, the current standard of care for curative therapy has a cure rate of less than 50%.
According to Maurie Markman, MD, patient-reported outcomes pertain to more relevant questions surrounding the impact of therapy for patients.
CancerNetwork® spoke with Neha Mehta-Shah, MD, MSCI, about the clinical landscape for patients undergoing treatment for rare lymphomas.
Related Content